London, Ontario company selling EpiSign METRIC, a clinically validated epigenomic diagnostic testing software that uses machine learning to identify DNA-methylation episignatures linked to rare genetic conditions.
Canadian innovation builds a brighter tomorrow.
London, Ontario company selling EpiSign METRIC, a clinically validated epigenomic diagnostic testing software that uses machine learning to identify DNA-methylation episignatures linked to rare genetic conditions.
Ontario corporation Episign Inc., status Active, registered office in London, Ontario, incorporated 2022-07-12. ised-isde.canada.ca
Address is 100 Collip Circle, Suite 120, London, ON, per its own site. episign.com
Runs a global research effort involving over 125 institutions in more than 25 countries, and covers greater than 113 conditions with EpiSign METRIC. episign.com
Launched EpiSign v6 on 29 June 2026 with expanded episignature coverage, and lists an Ontario Brain Institute partnership (March 2025) and an Ontario Genomics project (March 2026). episign.com
EpiSign METRIC platform launch (2025-10-15). episign.com
Products EpiSign publishes on its own site. Each card links to the page it was taken from.
Epigenomic diagnostic software
Company describes a cloud-based, clinically validated epigenomic diagnostic platform for genetic conditions that uses AI trained on its epigenetic database to identify DNA-methylation episignatures, integration-ready via APIs for labs, hospitals and research organizations. Launched 15 October 2025.
Learn morePublicly announced partnerships.
Partnership announced March 25, 2025 to advance diagnosis of rare genetic and neurological disorders using EpiSign's episignature technology.
Government support actually received. Unpublished amounts are left out.
Ontario Genomics — Synthetic Reference Epigenomics Initiative (secure cloud framework for rare-disease diagnostics)
Industrial Research Assistance Program – Contributions to Firms, National Research Council Canada — contribution
EpiSign announced the release of EpiSign™ version 6, the latest advancement of its DNA-methylation episignature classifier, with expanded episignature coverage and enhanced classification capabilities.
Sourced from the company's own pages or announcements.
Bekim Sadikovic
Founder and Chief Scientific Officer
Dan Sinai
President and Chief Executive Officer
Terms the company uses about its own work.
Other companies in AI.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.
